The efficacy of oral azithromycin in clearing ocular chlamydia: Mathematical modeling from a community-randomized trachoma trial  by Liu, Fengchen et al.
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Mass  oral  azithromycin  distributions  have  dramatically  reduced  the  prevalence  of  the  ocular  strains
of  chlamydia  that  cause  trachoma.  Assessing  efﬁcacy  of the  antibiotic  in  an  individual  is important  in
planning  trachoma  elimination.  However,  the  efﬁcacy  is difﬁcult  to  estimate,  because  post-treatment
laboratory  testing  may  be complicated  by  nonviable  organisms  or reinfection.  Here, we monitored
ocular  chlamydial  infection  twice  a year  in pre-school  children  in 32  communities  as  part  of a cluster-
randomized  clinical  trial  in  Tanzania  (prevalence  in children  was  lowered  from  22.0%  to  4.7%  after  3-yearathematical model
limination
zithromycin
AFE  strategy
rachoma
of  annual  treatment).  We  used  a mathematical  transmission  model  to  estimate  the  prevalence  of infec-
tion  immediately  after  treatment,  and  found  the  effective  ﬁeld  efﬁcacy  of antibiotic  in an  individual  to
be  67.6%  (95%  CI: 56.5–75.1%)  in  this  setting.  Sensitivity  analyses  suggested  that these  results  were  not
dependent  on speciﬁc  assumptions  about  the  duration  of  infection.  We  found  no  evidence  of decreased
efﬁcacy  during  the  course  of  the  trial. We  estimated  an  89%  chance  of  elimination  after  10  years  of  annual
treatment  with  95%  coverage.
014  T© 2
ntroduction
The World Health Organization (WHO) has targeted trachoma
or elimination by the year 2020 (Mariotti, 2004). Repeated mass
ral azithromycin distribution is a central component of the
AFE (Surgery of trichiasis, Antibiotics, Facial cleanliness and
nvironmental improvement) strategy endorsed by the WHO. The-
retically, repeated treatments may  eventually eliminate infection
rom even the most severely affected areas (Lietman et al., 1999;
elese et al., 2004), and mass antibiotic distributions have, in fact,
ramatically reduced the prevalence of infection in a number of
     
∗ Corresponding  author at: F.I. Proctor Foundation, UCSF, San Francisco, CA 94143-
412, USA. Tel.: +1 415 476 4101; fax: +1 415 476 0527.
E-mail address: travis.porco@ucsf.edu (T.C. Porco).
755-4365   © 2014 The Authors. Published by Elsevier B.V. 
ttp://dx.doi.org/10.1016/j.epidem.2013.12.001
Open access under the CC BY-NC-Nhe  Authors.  Published  by Elsevier  B.V. 
locations (Burton et al., 2010; Chidambaram et al., 2006; Gaynor
et al., 2003; House et al., 2009; Melese et al., 2004; Schachter et al.,
1999; Solomon et al., 2004; West et al., 2005). However, concern
remains that chlamydia may  develop resistance to the azalides and
macrolides, and that azithromycin may  lose efﬁcacy over time.
In vitro resistance has not been observed, although it is difﬁcult
to assess and rarely tested. Small surveys after one and after four
mass azithromycin distributions have failed to ﬁnd drug resistance
(Hong et al., 2009; Solomon et al., 2005).
The efﬁcacy of repeated oral azithromycin distributions has
been reported at the community level (Gaynor et al., 2003; Gebre
et al., 2012; Melese et al., 2008; Schachter et al., 1999). However, the
efﬁcacy in an individual (probability of clearance following treat-
ment) has been difﬁcult to assess; treated individuals may  become
infected between pre-treatment and post-treatment examinations
(which may  be as much as 6 months) even in carefully mon-
Open access under the CC BY-NC-ND license.itored communities. Although the true probability of clearance
following treatment cannot fully be assessed under ﬁeld conditions
because of reinfection and false positivity due to dead organisms
immediately after treatment, analysis of longitudinal prevalence
D license.
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uring trachoma elimination programs nevertheless reveals pro-
ound reductions in prevalence during treatment, as described
lsewhere (Chidambaram et al., 2006; Melese et al., 2004; Solomon
t al., 2004). Since these reductions occur because of the efﬁcacy of
he antibiotic in eliminating infection from individuals, analysis of
uch longitudinal prevalence curves reveals information about the
fﬁcacy. Lowered values for the individual efﬁcacy correspond to
maller reductions in prevalence and therefore longer elimination
imes. It is possible to estimate an effective ﬁeld efﬁcacy, which is
he value of the individual efﬁcacy most likely to yield an observed
revalence curve given constant transmission rates over the obser-
ation period and the antibiotic coverage. The effective ﬁeld efﬁcacy
an be used to estimate elimination times and program effective-
ess.
Here, we apply a mathematical transmission model to labora-
ory infection data from the Tanzanian portion of the Partnership
or the Rapid Elimination of Trachoma trial (PRET (Stare et al.,
011)) to estimate the effective ﬁeld antibiotic efﬁcacy in an indi-
idual in this setting.
ethods
linical  and laboratory results
Villages were monitored as part of a cluster-randomized tra-
homa treatment trial in Tanzania (the clinical trial registration
umber is NCT00792922) (Harding-Esch et al., 2010; Stare et al.,
011). In brief, 32 villages in Tanzania were randomized in a facto-
ial design (1) to high (80%) and very high (90% or more) coverage
ith annual mass antibiotic treatment, and (2) for the application
f a discontinuation rule or no use of such a rule. None of the villages
ad discontinued treatment during the ﬁrst three years, and thus
ll 32 villages received treatment at baseline, 12, and 24 months.
t a mass distribution, all individuals were offered a single dose of
ral azithromycin (1 g in adults, and weight-based dosing designed
o provide approximately 20 mg/kg to children over age 6 months;
ounger children were treated with topical tetracycline). The cen-
us list of the community was used to monitor coverage, and as
ach resident presented for treatment, treatment was observed and
ecorded in the treatment log by a community treatment assistant.
eported coverage includes a small fraction of children who were
ffered tetracycline ointment; however, the percentage of children
eceiving tetracycline never exceeded 8%.
All 32 villages were censused at baseline, 12, 24, and 36 months.
ne hundred randomly selected children aged 0–5 years were
xamined at baseline, and at 6, 12, 18, 24, 30 and 36 months after
aseline. A dacron swab was passed 3 times over their inverted right
pper conjunctiva, and processed for the presence of chlamydial
NA as previously described (Stare et al., 2011). The estimated
revalence of infection at 6, 12, 18, 24, 30, and 36 months was  used
o ﬁt parameters in the stochastic transmission model. Individual
evel infection data were not available for all members of the pop-
lation, since only a random sample of individuals was subjected
o polymerase chain reaction (PCR) testing in general.thics statement
The study received ethical approval from institutional review
oard (IRB) of the Johns Hopkins University School of Medicine, the
dp(k)0
dt
= p(k)1 ,
dp(k)
i
dt
= ˇ (i  − 1)(N − i + 1)
N
p(k)
i−1 + (i + 1)p
(k)
i+1 − ˇ
i(N
dp(k)
N
dt
= ˇ N  − 1
N
p(k)
N−1 − Np
(k)
N
+ p(k)
N−1 6 (2014) 10–17 11
University of California San Francisco, and the Tanzanian National
Institute for Medical Research, and was  carried out in accordance
with the Declaration of Helsinki. All subjects provided informed
consent. The informed consent given was oral, because (1) verbal
consent is the most ethical way to obtain consent, due to the high
illiteracy rates in the study area, (2) IRB approved the use of the
oral consent procedure for this study and (3) this oral consent is
documented on the registration form for each study participant
prior to examination in the ﬁeld.
Modeling methods
We  modeled village chlamydial positivity rates at baseline, and
at 6, 12, 18, 24, 30 and 36 months in each of 32 villages. The observed
data consisted of (1) the number S(l)
j
of PCR-positive individuals
in the random sample with size of M(l)
j
at each observation time
point l (l = 0, 1, . . .,  6 corresponding to baseline, 6, 12, 18, 24, 30
and 36 months, respectively) for village j (j = 1, . . .,  32), and (2) the
number of individuals reported to have been covered by antibiotics
at treatment time point k (k = 1, 2, 3 corresponding to baseline, 12
and 24 months).
Because reinfection may  occur following treatment, we  esti-
mated the efﬁcacy of treatment using a stochastic transmission
model of transmission of Chlamydia trachomatis over time, similar
to models previously published (Blake et al., 2009; Lietman et al.,
2011; Ray et al., 2007, 2009). We  ﬁtted this mathematical model
to the infection data using the maximum likelihood method. The
model contains three components: (1) random sampling of indi-
viduals for PCR testing at the observation times, (2) change in the
number of infected individuals over time due to transmission and
recovery, and (3) change in the number of infected individuals due
to mass antibiotic treatment with the reported coverage levels (at
baseline, 12 and 24 months). Observations from different villages
were considered independent.
Individuals  were assumed to have been sampled at random. Let
Sj be the number of positive individuals detected in the sample at
the end of twelve months (for village j). From village j with pop-
ulation size Nj of which the number Yj of infectives equals i, the
probability P(Sj = s|Yj = i) that s positives are observed from a sample
of size Mj is given by
(
i
s
)  (
Nj − i
Mj − s
)
/
(
Nj
Mj
)
using the hyper-
geometric distribution. For village j (j = 1, . . .,  32), we assumed a
population of size Nj, taken from the number of pre-school chil-
dren found in the census at the time of treatment (at baseline, 12
or 24 months).
To  model the change in prevalence between the prevalence
surveys based on above assumptions, we used a classical SIS
(susceptible-infective-susceptible) model structure, assuming that
the force of infection is proportional to the prevalence of infection
in the population with proportionality constant ˇ. Moreover, we
also assumed a constant exogenous force of infection  from out-
side the village (i.e., representing a risk which is independent of
the village prevalence). Finally, we  assumed a constant per-capita
recovery rate  . Between periods of treatment, we assumed that
the probability p(k)
i
(t) that there are i infectives in the population at
time t after treatment time point k obeys the following equations
for each village j (suppressing the subscript for clarity): − i)
N
p(k)
i
− ip(k)
i
− p(k)
i
(N − i) + p(k)
i−1(N − i + 1), for 1 ≤ i ≤ N − 1 (1)
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here  ˇ is the transmission coefﬁcient,  is the risk of infection
rom outside the village,  is the recovery rate, i and N indicate the
umber of infective individuals and total population of the village
t time t, and k is the time point of treatment.
To model treatment, we  assumed each individual in village j has
robability c(k)
j
of receiving treatment for treatment period k (k = 1,
, 3), where c(k)
j
is the probability that each child (whose age is
etween 0 and 5) in village j receives treatment in the kth treat-
ent; note that treatment is assumed to occur at a speciﬁc time for
veryone. The antibiotic efﬁcacy at treatment k is denoted as ek. We
ave assumed that the probability of treatment is independent of
nfection status, though some evidence indicates that individuals
ho do not participate in mass azithromycin-based anti-trachoma
ampaigns may  have a somewhat lower risk of infection (Amza
t al., 2013; Keenan et al., 2012b).
We modeled each treatment according to p(k)
i
(t = 0) =
Nj
i′=0p
(k,pre)
i′
(
i′
i
)
(1 − c(k)
j
ek)
i
(c(k)
j
ek)
i′−i
, where i′ is the num-
er of infected individuals eligible for treatment, and p(k,pre)
i′ is
he probability of i infected individuals before treatment time
oint k. For simplicity, we  assumed a standard beta-binomial prior
(Y = y) =
(
Nj
y
)
B(y + , Nj − y + )/B(, ) (where the shape
arameters  and  for each treatment were computed from the
bserved distribution of infection of 32 villages at baseline, 12 and
4 months, and B(z1, z2) is the beta function (Abramowitz and
tegun, 1972)); as a sensitivity analysis, we chose the special case
 =  = 1, yielding a uniform prior. The pre-treatment prevalence
istribution was then computed for each village by applying Bayes’
heorem:
(k,pre)
i
= P(Y = i|S = s) = P(S  = s|Y = i)P(Y = i)∑Nj
i=0P(S = s|Y = i)P(Y = i)
(2)
For  each village j, we used the most recent census data to
etermine the village size Nj. The initial condition is determined
rom Eq. (2), and the system numerically integrated for twelve
onths according to Eq. (1). Speciﬁcally, for each village j, the
re-treatment distributions of 1st, 2nd and 3rd treatments are
(1,pre)
i
= P(Y = i|S = S(0)
j
), p(2,pre)
i
= P(Y = i|S = S(2)
j
) and p(3,pre)
i
=
(Y  = i|S = S(4)
j
), respectively (where S(0)
j
is the observed number
f positive individuals (before the 1st treatment) at baseline in vil-
age j, S(2)
j
is the observed number of positive individuals (after
he 1st treatment and before the 2nd treatment) at 12 month in
he same village, and S(4)
j
is the observed number of positive indi-
iduals (after the 2nd treatment and before the 3rd treatment) at
4 month). Given the number i of infected individuals, we com-
ute the probability of the observed data of treatment k in village j
ccording to
N
(
i
)(
Nj − i
)(Sj = s) =
j∑
i=0
p(k)
i
()
s Mj − s(
Nj
Mj
)
where Mj here denotes the sample size at the end of the period
, and  is the interval between two observations). Speciﬁcally,
he probability of the observed PCR-positive individuals after
achtreatment k in each village j can be represented as 6 (2014) 10–17
P(Sj = S(2)j ) =
Nj∑
i=0
p(k=1)
i
(t = 12)
(
i
S(2)
j
)( Nj − i
M(2)
j
− S(2)
j
)
(
Nj
M(2)
j
) ,
P(Sj = S(4)j ) =
Nj∑
i=0
p(k=2)
i
(t = 12)
(
i
S(4)
j
)( Nj − i
M(4)
j
− S(4)
j
)
(
Nj
M(4)
j
) ,
and
P(Sj = S(6)j ) =
Nj∑
i=0
p(k=3)
i
(t = 12)
(
i
S(6)
j
)( Nj − i
M(6)
j
− S(6)
j
)
(
Nj
M(6)
j
) ,
respectively (where S(2)
j
and M(2)
j
are observed numbers of positive
individuals and sample size in village j at 12 month, S(4)
j
and M(4)
j
are observed number of positive individuals and sample size in the
village at 24 month, S(6)
j
and M(6)
j
are observed number of positive
individuals and sample size at 36 month, p(k=1)
i
(t = 12) is the proba-
bility that village j has i infections at 12 month (12 months after the
1st treatment at baseline), p(k=2)
i
(t = 12) is the probability of i infec-
tions at 24 month (12 months after the 2nd treatment at 12 month),
and p(k=3)
i
(t = 12) is the probability of i infections at 36 month (12
months after the 3rd treatment at 24 month)). Finally, we assume
independent villages, so that the total loglikelihood at time 
months after each treatment k may  be computed by summing over
all 32 villages
∑32
j=1 log
(∑Nj
i=0p
(k)
i
()
(
i
s
)  (
Nj − i
Mj − s
)
/
(
Nj
Mj
))
,
speciﬁcally, the equation for the likelihood of three treatment peri-
ods is
3∑
k=1
32∑
j=1
log
⎛
⎜⎜⎜⎜⎝
Nj∑
i=0
p(k)
i
()
(
i
S(2k)
j
)( Nj − i
M(2k)
j
− S(2k)
j
)
(
Nj
M(2k)
j
)
⎞
⎟⎟⎟⎟⎠ .
Statistical methods
We  estimated the efﬁcacy e for the study period, assuming a
mean recovery time of 6 months ( = 1/6 month−1); previous mod-
els have estimated the recovery time to be from 3 to 12 months
(Lietman et al., 2011; Ray et al., 2007, 2009) (  ˇ was jointly estimated
along with the efﬁcacy;  was assumed to be zero for the base case,
so no imported infection occurs). Likelihood optimization was con-
ducted using the Nelder–Mead downhill simplex method (Nelder
and Mead, 1965) as implemented in the optim function of the R
statistical package (each optimization had at least 8 different ini-
tial values). We then estimated the efﬁcacies e1, e2 and e3 for the
ﬁrst period (0–12 months), the second period (12–24 months) and
the third period (24–36 months), respectively. For the base case
scenario, we estimated the standard errors and conﬁdence inter-
vals of the estimated overall efﬁcacy as well as the period speciﬁc
emics
e
a
r
t
t
e
t
d
i
i
f
t
t
m
t
s
b
j
m
1
s
a
r
T
i
i
N
)
w
p
n
p
a
T
p
p
2
R
R
a
3
m
0
m
9
T
a
(
m
8
(F. Liu et al. / Epid
stimates by using bootstrap resampling of villages. A 64-core par-
llel computing platform was used for bootstrap resampling (to
educe the computational costs, each of the 64 CPUs ran 6 itera-
ions; 384 iterations were conducted). To test the hypothesis that
here is no change in the efﬁcacy over time, we ﬁrst computed the
fﬁcacy for each village and time, and then used Page’s L test of
rend (Siegel and Castellan, 1988) to assess both increasing and
ecreasing trends.
We  conducted the following sensitivity analyses. First, we var-
ed the recovery time (1/) from 3 to 18 months, assuming no
nﬂow of infection ( = 0). We  next allowed the rate of infection
rom outside the community, , to be another unknown parameter
o be estimated, and assumed the same values for the recovery rate
o test whether the inﬂow of infection has inﬂuence on the esti-
ated efﬁcacy. To determine whether the method for initializing
he ordinary differential equations could have affected our conclu-
ions, we repeated the analysis assuming a uniform instead of the
eta-binomial prior. For each of these, we used the leave-one-out
ackknife method to evaluate the standard errors (yielding slightly
ore conservative, i.e. larger standard errors (Efron and Tibshirani,
993) at considerably smaller computational cost.) For a ﬁnal sen-
itivity analysis, we modiﬁed the force of infection by including
n additional nonlinear term representing departure from a linear
elationship between the prevalence and risk (Lietman et al., 2011).
his yields the following equation for the change in the number of
nfected individuals between treatments:
dp(k)0
dt
= p(k)1
dp(k)
i
dt
= ˇ
(
(i − 1)
N
+ v2
(
i − 1
N
)+2)
(N − i + 1)p(k)
i−1 + (i + 1)p
(k)
i+1 − ˇ
(
i
N
+ v2
(
dp(k)
N
dt
= ˇ
(
(N − 1)
N
+  v2
(
N − 1
N
)+2)
p(k)
N−1 − Np
(k)
N
+ p(k)
N−1
We  used Eq. (3) (with the estimates of v2 and  in our previous
ork (Lietman et al., 2011)) to estimate the efﬁcacy assuming the
resence of this non-linear term.
Finally, to predict the critical coverage level (compliance)
eeded  for eradication within 10 years, we used the transmission
arameters (ˇ, ) and the efﬁcacy of the antibiotic estimated above,
nd varied the coverage level from 60% to 100% for all villages.
hen, we simulated (100 replications for each village) the average
revalence for all villages within ten years of treatment. All com-
utations were performed using the R statistical program (version
.13 R Foundation for Statistical Computing, Vienna, Austria) on the
TI MIDAS cluster (http://www.epimodels.org).
esults
The  numbers of children aged 0–5 at baseline, 6, 12, 18, 24, 30,
nd 36 months tested for the presence of ocular chlamydia were
199, 3198, 3191, 3200, 3199, 3194 and 3153, respectively. The
ean of number of sampled children per village was 99.97 (SD
.18) at baseline, 99.94 (SD 0.35) at 6-month, 99.72 (SD 0.99) at 12
onths, 100 (SD 0.00) at 18 months, 99.97 (SD 0.18) at 24 months,
9.81 (SD 1.06) at 30 months, and 98.53 (SD 3.33) at 36 months.
he estimated prevalence of ocular chlamydial infection by PCR
t baseline was 22.0% (cover all villages), with standard deviation
SD) 10.1%. At 6 months the prevalence was 10.5% (SD 4.7%), at 12
onths 13.0% (SD 6.4%), at 18 months 7.1% (SD 4.4%), at 24 months
.6% (SD 7.3%), at 30 months 3.5% (SD 2.5%), and at 36 months 4.7%
SD 3.3%) (Fig. 1). The mean antibiotic coverage for all communities 6 (2014) 10–17 13
+2
)
(N − i)p(k)
i
− ip(k)
i
− p(k)
i
(N − i) + p(k)
i−1(N − i + 1), for 1 ≤ i ≤ N − 1, and
(3)
was estimated to be 93.7% (SD 5.1%) at baseline, 90.1% (SD 5.4%) at
12 months, and 89.6% (SD 4.6%) at 24 months.
Assuming that the mean duration of infection is 6 months (i.e.,
the recovery rate  is 1/6 month−1) (Table 1), we found that the
estimated effective ﬁeld efﬁcacy was 67.6% (95% CI: 56.5–75.1%)
assuming an equal efﬁcacy for three years. Year-speciﬁc effective
ﬁeld efﬁcacy estimates are 64.6% (95% CI: 56.5–75.1%) for the ﬁrst
year (eˆ1), 65.9% (95% CI: 51.8–80.0%) for the second year (eˆ2), and
76.7% (95% CI: 63.5–89.8%) for the third year (eˆ3) (Table 2). Using
Page’s L test, we found no evidence of any change in the effective
ﬁeld efﬁcacy.
Sensitivity analyses for these ﬁndings are presented in
Tables 1 and 2. Assuming a recovery time of 12 months yielded
a slightly higher estimated effective ﬁeld efﬁcacy for the study
period: 70.7% (95% CI: 62.4–79.0%, jackknife method); we  found
an effective ﬁeld efﬁcacy of 72.0% (95% CI: 64.0–80.0%, jackknife
method) when the mean duration of infection was  18 months
and an effective ﬁeld efﬁcacy of 62.5% (95% CI: 50.1–74.9%, jack-
knife method) when the mean duration of infection was 3 months
(Table 1). Adding an external infection term into the model yielded
a slight increase (ranging from 0.02% to 2%) in the estimated effec-
tive ﬁeld efﬁcacy for all values of the mean duration of infection we
examined (Table 1). We  also chose a uniform prior to initialize the
ordinary differential equations, and found that this yielded slightly
higher estimates of the effective ﬁeld efﬁcacy as well: 71.9% (95% CI:
62.4–81.4%), 74.3% (95% CI: 65.7–83%), 75.3% (95% CI: 66.6–84.0%)
and.68.1% (95% CI: 57.1%, 79.2%) for mean durations of infection of
6, 12, 18 and 3 months, respectively (conﬁdence intervals derived
by the jackknife method) (Table 1). One village (in Fig. 1) appears
to have different dynamics than other 31 villages. To evaluate how
sensitive the estimates in Table 1 are to that village, we  used the
observed data from the remaining 31 to estimate the effective ﬁeld
efﬁcacy and transmission coefﬁcient under the base case scenario,
and found that the estimated effective ﬁeld efﬁcacy was 65.8% (95%
CI: 55.5–74.7%, bootstrap method), and the transmission coefﬁcient
was 0.221 (95% CI: 0.197–0.256).
As a ﬁnal sensitivity analysis, we added the non-linear incidence
term, and found the estimated common effective ﬁeld efﬁca-
cies (durations of infection: 6, 12, 18 and 3 months) for three
years were 66.9% (95% CI: 57.8–75.9%) with log-likelihood value
of −530.682, 70.5% (95% CI: 62.3–78.6%) with log-likelihood value
of −534.4659, 70.8% (95% CI: 62.6–79.4%) with log-likelihood value
of −537.3769, and 60.9% (95% CI: 49.4–72.4%) with log-likelihood
value of −532.483. These estimates are slightly lower than efﬁcacies
estimated with the linear term. Conﬁdence intervals were derived
using the jackknife method.
Based on the above estimates for the efﬁcacy in the base case sce-
nario, we  simulated trachoma transmission with constant efﬁcacy
over times in each village to derive the probability of elimina-
tion (deﬁned as the absence of infection and transmission). With
an antibiotic efﬁcacy of 67.6% (95% CI: 56.5–75.1%) and a mean
duration of infection of 6 months, we found that the elimination
probability after 10 years treatment was 95.0% (SD 4.1%) assum-
ing complete coverage, and 89.2% (SD 5.6%) with coverage of 95%.
When coverage levels of 90%, 80%, 70% and 60% were assumed, we
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Table  1
Estimated effective ﬁeld efﬁcacy based on the data of 32 villages. We  estimated the overall efﬁcacies under the base case (6-month infection duration, no infection from
outside community and beta-binomial distribution of infectious population before treatment) and sensitivity analysis scenarios of different durations of infection (6, 12, 18
and  3 months), different distributions of infectious population before treatment (beta-binomial and uniform), and different infection from outside community (included or
not).  The base case was done by using Bootstrap method and sensitivity analysis scenarios were done by using Jackknife method.
Scenario Duration of infection Distribution of infectious
population  before treatment
Efﬁcacy eˆ (95%  C.I.) ˆˇ (95%  C.I.) ˆ (S.D.) Log-likelihood
value
Base Case 6-montha Beta-binomial 0.676 (0.565, 0.751) 0.229 (0.202, 0.262) – −532.579
Varying  attack duration 12-month Beta-binomial 0.707 (0.624, 0.790) 0.146  (0.117, 0.174) –  −535.762
18-month Beta-binomial 0.720 (0.640, 0.800) 0.119 (0.091, 0.143) – −538.468
3-month Beta-binomial 0.625 (0.501, 0.749) 0.401 (0.366, 0.436) – −535.554
Infection  from outside
community  included ()
6-month Beta-binomial 0.683 (0.598, 0.768) 0.226 (0.187, 0.264) 0.0003 (9.4e−5) −532.237
12-month Beta-binomial 0.707 (0.566, 0.847) 0.143 (0.102, 0.185) 0.0002 (9.8e−5) −535.643
18-month Beta-binomial 0.721 (0.647, 0.796) 0.118 (0.082, 0.154) 0.0001 (8.6e−5) −538.409
3-month Beta-binomial 0.645 (0.541, 0.750) 0.396  (0.353, 0.440) 0.0006  (1.0e−4) −534.709
6-month Uniform 0.719 (0.624, 0.814) 0.224 (0.185, 0.264) 0.0008 (9.4e−5) −543.023
12-month Uniform 0.743 (0.657, 0.830) 0.143 (0.105, 0.180) 0.0006 (8.5e−5) −548.985
18-month Uniform 0.753 (0.666, 0.840) 0.117 (0.078, 0.155) 0.0006 (8.2e−5) −552.814
3-month Uniform 0.681 (0.571, 0.792) 0.394  (0.351, 0.438) 0.0012 (1.1e−4) −542.268
Initialization 6-month Uniform 0.702 (0.606, 0.798) 0.233 (0.200, 0.266) – −545.475
12-month Uniform 0.735 (0.648, 0.821) 0.151 (0.118, 0.183) – −550.937
18-month Uniform 0.747 (0.664 0.830) 0.125 (0.092, 0.157) – −554.559
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a Estimation was  done by using Bootstrap method.
ound the probability of elimination was 81.8% (SD 8.8%), 59.6% (SD
4.8%), 34.7% (SD17.5%) and 16.4% (SD 14.3%), respectively (Fig. 2).
More generally, we may  theoretically assess elimination by
ass treatment by requiring sufﬁcient coverage and efﬁcacy
hat effective reproductive number Reff = exp((  ˇ − ))(1 − ec) < 1
where  is the interval between two treatments, c is coverage,  ˇ is
he transmission coefﬁcient, 1/ is the mean duration of infection,
nd e is the efﬁcacy) (Melese et al., 2004). The estimated efﬁcacy
f 67.6% (Reff = 0.68) is higher than the critical efﬁcacy level 52.6%
ig. 1. The estimated and the observed prevalence of ocular chlamydial infection in
hildren aged 0–5 years over time. Each gray curve represents the observed preva-
ence in a single community over time, with 3-year treatments. The red points
epresent  the observed mean prevalence of the 32 communities at baseline, 6, 12, 18,
4, 30 and 36 months. The blue curve shows the simulated mean prevalence based
n estimates of common beta (0.228) and different effective ﬁeld efﬁcacies (64.6%
t 1st treatment, 65.9% at 2nd treatment, and 76.7% at 3rd treatment) in Table 2.
ral azithromycin was  distributed to communities at 0, 12 and 24 months. Each
ommunity was assessed by randomly selecting 100 children. (For interpretation of
he references to color in ﬁgure legend, the reader is referred to the web  version of
he article.)48 (0.528, 0.768) 0.404 (0.367, 0.440) – −545.411
needed for annual treatment to eliminate infection with perfect
coverage ( = 12 months, 1/ = 6 months,  ˇ = 0.229, and c = 100%),
implying that annual mass treatment could eventually eliminate
the infection.
As  sensitivity analysis of different infection durations, we also
simulated trachoma transmission under three 10-year treatments
with 12 months infection duration and the corresponding effective
ﬁeld efﬁcacy of 70.7% (95% CI: 62.4–79.0%), 18 months infection
duration and corresponding efﬁcacy of 72.0% (95% CI: 64.0–80.0%),
and 3 months infection duration and the corresponding efﬁcacy of
62.5% (95% CI: 50.1–74.9%). Assuming complete coverage, the simu-
lated elimination probabilities after 10-year treatments were 94.1%
(SD 3.1%) for infection duration of 12 months, 94.4% (SD 3.6%) for
infection duration of 18 months, and 94.1% (SD 4.2%) for infection
duration of 3 months. When coverage levels of 95%, 90%, 80%, 70%
and 60% were assumed, we  found that the probability of elimination
with infection duration of 12 months was 86.8% (SD: 7.6%), 73.6%
(SD 11.4%), 40.9% (SD 18.3%), 15.4% (SD 15.0%) and 4.6% (SD 10.8%),
respectively (Fig. 3 in Supplement); the probability of elimination
with infection duration of 18 months was 85.6% (SD: 6.5%), 70.9%
(SD 12.5%), 32.3% (SD 18.4%), 10.9% (SD 15.4%) and 2.9% (SD 8.9%),
respectively (Fig. 1 in the Supplement); the probability of elimina-
tion with infection duration of 3 months was  90.6.8% (SD: 5.9%),
85.3% (SD 7.9%), 71.8% (SD 12.8%), 57.3% (SD 16.8%) and 40.2% (SD
17.9%), respectively (Fig. 2 in the Supplement).
Discussion
Applying a transmission model to data collected from a 32-
village, cluster-randomized trachoma elimination trial in Tanzania,
we estimated an effective ﬁeld efﬁcacy of oral azithromycin in
clearing the ocular chlamydial strains that cause trachoma. Specif-
ically, we  used a transmission model to ﬁnd the efﬁcacy of oral
azithromycin most likely to have resulted in the observed data
pre-treatment, 6 and 12 months after each treatment, given val-
ues for the coverage. This effective ﬁeld efﬁcacy was estimated to
be 67.6%. This estimate is lower than the clearance rates of 92–98%
which had been reported in genital chlamydia and assumed in pre-
vious trachoma transmission models (Erdogru et al., 1995; Hillis
et al., 1998; Lietman et al., 1999; Magid et al., 1996; Stamm et al.,
1995; Steingrímsson et al., 1994; Thorpe et al., 1996; Wehbeh et al.,
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Table  2
Difference in effective ﬁeld efﬁcacy among three periods. We  estimated three different effective ﬁeld efﬁcacies under scenarios of different durations of infection (6, 12, 18
and  3 months) and different distributions of infectious population before treatment (beta-binomial and uniform).
Duration of
infection
Distribution  of infectious
population  before treatment
Efﬁcacy ﬁrst period eˆ1
(95% C.I.)
Efﬁcacy second period eˆ2
(95% C.I.)
Efﬁcacy third period eˆ3
(95% C.I.)
ˆˇ (95%  C.I.) Log-likelihood
value
6-month Beta-binomial 0.646 (0.565, 0.728) 0.659 (0.518, 0.800) 0.767 (0.635, 0.898) 0.228 (0.199, 0.258) −528.235
12-month  Beta-binomial 0.687 (0.616, 0.759) 0.690 (0.563, 0.817) 0.791 (0.671, 0.912) 0.146 (0.117, 0.175) −530.886
18-month  Beta-binomial 0.702 (0.625, 0.780) 0.703 (0.578, 0.828) 0.801 (0.677, 0.926) 0.120 (0.089, 0.150) −533.339
3-month  Beta-binomial 0.571 (0.461, 0.683) 0.612 (0.439, 0.784) 0.726 (0.571, 0.881) 0.400 (0.366, 0.434) −531.755
6-month  Uniform 0.667 (0.585, 0.748) 0.688  (0.551, 0.825) 0.799 (0.684, 0.913) 0.233 (0.201, 0.265) −539.776
12-month Uniform 0.707 (0.490, 0.923) 0.718 (0.420, 0.965) 0.821 (0.566, 0.926) 0.150 (0.080, 0.221) −544.460
18-month  Uniform 0.727 (0.660, 0.792) 0.734 (0.612, 0.857) 0.834 (0.734, 0.935) 0.125 (0.095, 0.156) −547.716
3-month  Uniform 0.587 (0.475, 0.698) 0.636 (0.470, 0.802) 0.755 (0.618, 0.891) 0.402 (0.367, 0.438) −540.545
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iig. 2. The probability of elimination by repeated mass treatment within 10 yea
eintroduction of infection. Each line represents the probability of elimination happ
ase  scenario (67.6% effective ﬁeld efﬁcacy, and a mean duration of infection of six 
998). More recently, the efﬁcacy of azithromycin in clearing the
exually transmitted infection was estimated to be 77%, lower than
reviously thought (Handsﬁeld, 2011; Schwebke et al., 2011).
One  possible explanation for ﬁnding a lower efﬁcacy estimate
han previously found is the acquisition of macrolide resistance. If
resent, we would expect resistant strains to be selected for with
he ﬁrst mass treatment, and a progressively lower observed efﬁ-
acy with each mass treatment. There were a few villages treated
n previous years going back to 1999, but no Kongwa-wide mass
reatment until the start of the PRET study (S. West, pers. commun.).Our estimate may  be biased for several reasons. Our base case
odel assumed that transmission is proportional to the number
f infectious cases and number of susceptible cases (mass action);
f this is not the case, then this may  have masked increasedwn for 100%, 95%, 90%, 80%, 70% and 60% coverage levels, assuming no external
over time for a speciﬁc antibiotic coverage using the estimated efﬁcacy for the base
s).
transmission at the later, lower prevalence (Lietman et al., 2011).
Similarly, uncertainty in either the average duration of infection or
in the distribution of infection times is a potential source of model
misspeciﬁcation, although a sensitivity analysis suggests that
efﬁcacy estimates remain low over a wide range of assumptions.
Furthermore, the Roche Amplicor test may not have detected all
cases of infection, either before or after treatment (Keenan et al.,
2012a; Yang et al., 2007). Even though the trial from which these
data came is one of the larger trachoma studies performed, 32 com-
munities may  not be a large enough sample size to offer a precise
estimate of efﬁcacy, and the conﬁdence interval for our estimate
is broad. Loss of immunity was  not considered in this model (anal-
ysis suggests a similar transmission coefﬁcient at each follow-up
period (Liu et al., 2013), contrary to expectations if loss of immunity
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layed an important role). We  also observe that if children who
eceived antibiotics were more likely to be infected (Amza et al.,
013; Keenan et al., 2012b), then we expect that our estimates
f the efﬁcacy are biased upward (because the true probability of
reatment is higher than the coverage). Our model assumed that
hildren were treated with azithromycin only, however, some
hildren (0–6 months) were treated with topical tetracycline, and
his could be potential bias even though the percentage of children
eceiving tetracycline never exceeded 8%. Finally, these results
re dependent on the accuracy of the census. If children were not
dentiﬁed and treated, the effective antibiotic coverage may  have
een lower than recorded, resulting in an underestimate of antibi-
tic efﬁcacy. Several ﬁeld control measures were instituted to
nsure accurate census information, and all Community Treatment
ssistant data on coverage was independently veriﬁed.
We  modeled infection from outside the population of children
n each community using a simple constant exogenous infection
ate. Such exogenous infection may  represent introduction from
utside the community, or a ﬁrst approximation to infection from
lder children or adults within the same community. Of course,
uch models could be further reﬁned to reﬂect age structured
ransmission dynamics. In this setting, the other age groups (older
hildren and adults) were being treated as well, and other stud-
es have shown consistently higher prevalence in small children
han in other age groups (e.g. Solomon et al., 2004). Previous stud-
es have shown that treatment restricted to children can lower the
revalence in adults (House et al., 2009).
In our model, the transmission coefﬁcient is determined by the
onstellation of factors which affect transmission. To the extent
hat transmission is reduced by the F and E components of the
AFE strategy, the estimated transmission coefﬁcients would be
maller. Face washing (Ejere et al., 2012) and environmental sani-
ation (Rabiu et al., 2012; Stoller et al., 2011; West et al., 2006) for
rachoma control, while less well supported by current literature
han antibiotic distribution for trachoma control, could reduce the
ransmission coefﬁcient and thereby enhance trachoma elimina-
ion. Estimates of the transmission coefﬁcient in one setting could
ot be straightforwardly applied to other regions or times.
Models  have predicted that with high coverage of an efﬁca-
ious antibiotic, repeated distributions can eliminate infection from
ven the most severely affected communities (Lietman et al., 1999;
elese et al., 2004). Longitudinal studies have validated that local
limination is possible (Biebesheimer et al., 2009; Gaynor et al.,
003; Gill et al., 2008; Melese et al., 2008; Solomon et al., 2004). In
 population that has received previous rounds of mass treatment,
e found a lower efﬁcacy of antibiotic than had been assumed.
owever the WHO-recommended 80% coverage and repeated
ounds of treatment are projected to lead to substantial declines in
rachoma prevalence and may  even lead to complete elimination
f infection.
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